Recently, a new generation of synthetic biology enzyme computing design platform - Huili Biotech announced the completion of nearly 3 million yuan of Series A financing, jointly led by Legend Capital and Boyuan Capital, followed by Qianji Capital, Yunqi Capital and Zhongwei Capital, and Taihe Capital served as financial advisors. This round of financing will be used to accelerate the construction and operation of large-scale production facilities, the R&D of new product pipelines, and the expansion of talent teams.

 

 

Regarding this financing, Ji Haiquan, executive director of Legend Capital, said: "The synthetic biomaterials market is broad and is an important area in the direction of green and low-carbon. As the core component of synthetic biology, the design and transformation of enzymes will bring low-cost and sustainable green production methods to more traditional biotechnology industries. Legend Capital has long focused on investment in the 'IT+' industry, and Huili Biotech is a model of the combination of information technology and biotechnology (IT+BT). The company's team background combines production and research, and has differentiated product selection and multi-pipeline extension capabilities. The company has mastered the industry-leading enzyme calculation design technology, and quickly realized the large-scale production of high value-added products such as pharmaceutical intermediates through the layout of the whole industrial chain, and has been fully recognized by leading customers in the industry; Junlian is very pleased to work hand in hand with the company to contribute to China's biological 'intelligence'. ”

Ma Jinbo, Vice President of Investment of Boyuan Capital, said: "ESG concept has become a global consensus, and low-carbon, environmental protection, green and sustainable development will become the main direction of social progress, and it is also the focus and overall layout of Boyuan. Boyuan adheres to the concept of 'disruptive technology as a barrier, core scientific and technological talents as the basis, and high added value brought by sustainable development application as the goal', and has laid out a number of high-quality companies in the field of synthetic biology, among which Huili is one of the few companies that we understand has a complete industrialization from design to production in multiple varieties. With the R&D team's deep understanding of biocatalysis-related component mining, mechanism analysis, enzyme engineering transformation, synthesis design, and the original full-scenario enzyme engineering calculation and design platform, and the industry veterans with more than 30 years of practical experience in the biological/chemical industry, Huili has great advantages and characteristics in terms of product selection and cost. It is believed that in the process of low-carbon transformation and sustainable development of the domestic chemical industry, Huili Biotech will become an important leader. ”

Shen Xiaoyin, Managing Director of Qianji Capital, said: "With the maturity of sequencing, gene editing, protein structure prediction and other base technologies, we believe that the application of synthetic biology in the field of biomanufacturing is a long-term change trend in the future on a global scale. At the same time, China's large-scale fermentation industry, which is more mature than Europe and the United States, also provides a good development soil for the implementation of synthetic biology technology. We are optimistic that Huili's enzyme engineering calculation and design platform will greatly improve the R&D efficiency, and the team's accumulation of decades of experience in the field of production process scale-up, and believe that the company can promote the multi-faceted innovation of traditional production methods in the industry." ”

Yao Feng, Managing Director of Yunqi Capital, said: "Synthetic biology is an important area for the development of green economy and will become the next generation of technological revolution. We are very optimistic about Whaley's general-purpose computing power based on rational design of enzyme proteins, and become a leading company with multi-pipeline product capabilities in the field of synthetic biology." On the one hand, the team's underlying ability in enzyme protein design is at the leading level in China and even internationally; On the other hand, it has been proven in multi-pipeline and achieved mass production and large-scale sales. We look forward to working with the Huili team to make more cutting-edge progress in the field of synthetic biology and help the intelligent upgrading of the industrial chain." Xu Wei, partner of Zhongwei Capital, said: "Zhongwei Capital is optimistic about the opportunities in the synthetic biology industry for a long time, and enzymes are the key point for the application of synthetic biology. The Huili team is a rare combination of 'technology + industry' in the industry, and the team has both advanced enzyme engineering capabilities and decades of practical experience in the biochemical industry. The enzyme engineering computing platform built by Huili can greatly improve the efficiency of obtaining target enzymes, so as to realize pipeline commercialization relatively quickly. Huili's pipeline selection has a unique and clear positioning, and the market competitive advantage is obvious, and we look forward to the team continuing to grow and create more surprises after the completion of this round of financing. ”

Sun Si, Director of Taihe Capital, said: "R&D efficiency is the core element for enterprises in the field to establish advantages, and the Huili Biotech team has many years of successful experience in industrialization landing, and has achieved a closed loop of 'R&D-production-manufacturing' in several products. Through this round of financing, the company will further expand its leading edge in R&D efficiency and mass production capacity, and realize the landing and application of new products/new fields. We are very happy to become a long-term strategic partner of the company and continue to accompany the company's growth! ”